Sponsor study identifier
Secondary identifiers
NIH
REGISTRY · NCI Physician Data Query
observational
47
0 countries
N/A
Study Start
November 2005
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
March 2006
Actual (reported)Study Completion
August 2015
Actual (reported)RATIONALE: Collecting and storing samples of blood from patients with cancer to study in the laboratory may help doctors learn more about cancer and identify biomarkers related to cancer. PURPOSE: This laboratory study is looking at biomarkers of angiogenesis and disease in patients with unresectable malignant mesothelioma treated on clinical trial CALGB-30107.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
August 2015
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 2005
Date type not reportedThis date has not been verified as actual or estimated.
March 2006
Actual (reported)May 9, 2009
Actual (reported)May 12, 2009
Actual (reported)August 2015
Actual (reported)Level of biomarkers, including thrombospondin I, vascular endothelial growth factor receptor I, fibroblast growth factor, transforming growth factor, and mesothelin (high vs low)
baseline
Effect of biomarker expression level on overall survival
Up to 10 years
Serum samples previously obtained from patients on protocol CALGB-30107 are tested for levels of thrombospondin I serum, vascular endothelial growth factor receptor I, fibroblast growth factor, transforming growth factor, and mesothelin using enzyme-linked immunosorbent assays (ELISA).
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Patients previously enrolled on CALGB-30107 diagnosed with malignant mesothelioma.
Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.
Samples retained from patients participating on CALGB-30107.
Robert A. Kratzke, MD
Masonic Cancer Center, University of Minnesota
First Submitted
May 9, 2009
First Posted
May 12, 2009
Study Start
November 2005
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
March 2006
Actual (reported)Bortezomib in Treating Patients With Malignant Pleural Mesothelioma
Study Completion
August 2015
Actual (reported)Last Updated
January 24, 2019
Record last verified: 2019-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: